Atopic dermatitis is a chronic inflammatory skin disease that is very common in childhood.Among adults it is an increasingly common reason for consultation and is diagnosed with increasing frequency.Dupilumab is a monoclonal antibody that blocks the interleukin 4 (IL-4) receptor subunit ␣, decreasing activation of cells that express this receptor (mainly Th2 lymphocytes).The decreased polarization of naïve Th to Th2 lymphocytes results in a decrease in the secretion and function of the cytokines IL-4, IL-13, and IL-5.Naive Th lymphocytes are instead polarized to Th1 and Th17 lymphocytes, increasing the secretion of the corresponding cytokines.Therapeutic blockade of certain cytokines or their receptors causes certain immunological modifications.Beneficial effects have been described for several such therapies, mainly in patients with psoriasis, although paradoxical reactions occur in some patients.The persistence or de novo appearance of head and neck dermatitis, which is observed in up to 10% of the cases in